Dyadic outlines new commercial focus as first bulk protein sales and Asia expansion accelerate growth trajectory
Source: SeekingAlpha
2025-11-12 21:02:29 ET
More on Dyadic International
- Dyadic International, Inc. (DYAI) Q3 2025 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on Dyadic International
- Historical earnings data for Dyadic International
- Financial information for Dyadic International
Read the full article on Seeking Alpha
For further details see:
Dyadic outlines new commercial focus as first bulk protein sales and Asia expansion accelerate growth trajectory
Dyadic International Inc.
NASDAQ: DYAI
DYAI Trading
0.65% G/L:
$0.78 Last:
27,309 Volume:
$0.774 Open:
DYAI Latest News
March 04, 2026 07:20:00 am
Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)
March 02, 2026 07:20:00 am
Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone
February 17, 2026 07:25:00 am
Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin
DYAI Stock Data
$30,756,010
25,512,398
0.35%
21
N/A
Biotechnology & Life Sciences
Healthcare
US
Jupiter
